

2. **The Rejection of Claim 18 under 35 U.S.C. § 1.112 Should Be Withdrawn**

Claim 18 is objected to because it recites that "the mRNA coding sequence encodes G and F genes" In view of Applicants' amendment, the rejection should be withdrawn.

3. **The Objection to Claims 13, 25 and 26 Should Be Withdrawn**

Claims 13, 25 and 26 were objected to because these claims depend from a claim that has been objected to. In view of Applicants' amendment to claim 2, the objection to the claims that depend from claim 2 should be withdrawn.

CONCLUSION

Applicants respectfully request entry and consideration of the foregoing amendments and remarks. No new matter has been introduced. The claims are believed to be free of the art and patentable. Withdrawal of all the rejections and an allowance are earnestly sought.

Respectfully submitted,

by: *Jacqueline Benn*
Reg. No. 43,492

Date June 30, 2003

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

EXHIBIT A
CLAIMS AS PENDING UPON ENTRY OF THE AMENDMENT
FILED JUNE 30, 2003
IN U.S. PATENT APPLICATION SERIAL NO. 09/161,122
ATTORNEY DOCKET NO. 7682-045

2. (Currently Amended) An isolated infectious Respiratory Syncytial Virus (RSV) particle containing an RSV RNA comprising a binding site specific for an RNA-directed RNA polymerase operatively linked to an RSV RNA comprising sequence encoding antigenic polypeptides of both RSV-A and RSV-B.

13. (Previously Amended) A vaccine comprising a chimeric Respiratory Syncytial Virus (RSV) the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of an RSV and a pharmaceutically acceptable carrier.

18. (Currently Amended) The vaccine of Claim 13 in which the mRNA coding sequence encodes G and F proteins of both Respiratory Syncytial Virus A and Respiratory Syncytial Virus B.

25. (Previously Added) The isolated infectious Respiratory Syncytial Virus (RSV) particle of claim 2, wherein the RSV RNA further comprises a L gene mutation.

26. (Previously Added) The isolated infectious Respiratory Syncytial Virus (RSV) particle of claim 2, wherein the RSV RNA further comprises a deletion of M2-ORF1 and/or SH-ORF2.